Dr. Kyle A. Davis, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- In the NPI registry since
- 2014
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
IN license 01083879A -
Pediatrics Physician
IN license 01083879A · OH license 1124446984
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 3 companies reported 11 payments worth $9,583 in total to this clinician.
| Genzyme Corporation | $9,448 |
|---|---|
| Genentech USA, Inc. | $104 |
| Inari Medical, Inc. | $30.21 |
| Consulting Fee | $7,953 |
|---|---|
| Travel and Lodging | $1,132 |
| Food and Beverage | $497 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Sep 26, 2025 | Consulting Fee ALTUVIIIO · Hematology | $6,507 |
| Genzyme Corporation Mar 18, 2025 | Consulting Fee | $1,446 |
| Genzyme Corporation Sep 26, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Miami, FL · in-kind | $722 |
| Genzyme Corporation Sep 26, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Miami, FL · in-kind | $202 |
| Genzyme Corporation Sep 26, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Miami, FL · in-kind | $165 |
| Genzyme Corporation Sep 26, 2025 | Travel and Lodging ALTUVIIIO · Hematology · travel to Miami, FL | $43.62 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $34,312 in research payments for these studies, mostly to the institutions running them.
- Real-world Experience of Efanesoctocog Alfa Prophylaxis in US Patients with Hemophilia A
Sanofi US Services Inc. - Goal Attainment and Physical Activity in People With Hemophilia A
Sanofi US Services Inc. · Terminated · NCT06530030 - Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
Sanofi US Services Inc. · Recruiting · NCT06941870 - A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
Sanofi US Services Inc. · Active, not recruiting · NCT05911763
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.